Silicon Image Introduces 225 MHz HDMI v1.3 PHY IC and Soft Link IP Core for Consumer Electronics Applications
New Solution Offers Lower Cost and Faster Time-To-Market for HDMI v1.3 Transmitter Implementations
Silicon Image Introduces 225 MHz HDMI v1.3 PHY IC and Soft Link IP Core for Consumer Electronics Applications
Silicon Image, Inc. (NASDAQ:SIMG), a leader in semiconductors and intellectual property for the secure distribution, presentation and storage of high-definition content, today announced its 225 MHz HDMI™ version 1.3 PHY solution, consisting of the SiI9204 HDMI v1.3 transmitter PHY semiconductor and companion HDMI v1.3 link layer intellectual property (IP) core for use in consumer electronics and high-end mobile device applications. This latest offering complements the Silicon Image family of HDMI v1.3 transmitters which include stand-alone discrete semiconductors, PHY semiconductors for use with link layer IP cores and full HDMI v1.3 link and PHY IP cores.
Today, integrated circuit (IC) providers have the option of either using external discrete HDMI chips or fully integrating HDMI functionality into their consumer electronics ICs. Silicon Image now offers an HDMI v1.3 transmitter solution that provides the benefits of both approaches, with a lower bill-of-materials (BOM) cost compared to discrete IC implementations and faster time-to-market compared to a fully integrated system-on-a-chip (SoC) solution. In addition, Silicon Image’s HDMI v1.3 transmitter technology is a silicon-proven, high-volume solution that has shipped in more than 10 million HDMI v1.3 transmitter chips since 2007.
“HDMI version 1.3 is already the standard for digital TVs and is now becoming prevalent in high-definition digital set-top-box and Blu-ray Disc™ player implementations,” stated Ron Richter, director of business development at Silicon Image, Inc. “Silicon Image’s PHY IC and link IP core solution delivers the high-quality video and audio capabilities of HDMI v1.3 without the engineering challenges associated with an SoC analog integration.”
Key features of Silicon Image's SiI9204 transmitter PHY include:
- 225 MHz HDMI v1.3 support for Deep Color applications
- SiI9002 compatibility mode (for those who use SiI9002 today)
- Low power at high resolutions & frame rates (<90mW @ 1080p/60fps 12 bits/pixel)
- Low power down current (<10µA)
- Integrated CEC hardware support
- Display Data Channel (DDC) support
- Can support High Bit-Rate audio and x.v.Color with full featured SoCs
- 40-pin 6X6mm QFN package
- Competitive pricing for link IP core licensing and SiI9204 chip
The SiI9204 IC, with built-in Consumer Electronics Control (CEC), is ideal for consumer applications such as digital set-top-boxes, personal video recorders, Blu-ray Disc players, game consoles, high-definition (HD) camcorders and high-end mobile devices. The link layer IP core, designed to be integrated into an SoC, can be quickly targeted to any foundry or process, delivering a key time-to-market advantage when compared to a fully integrated mixed-signal solution.
Planned availability for the SiI9204 transmitter PHY is Q1 2009 and the accompanying link layer IP will be available for integration in Q4 2008. More information on the Silicon Image transmitter IC and IP core solutions can be found at www.siliconimage.com . Companies, engineers and developers interested in additional information should contact Ron Richter at Tel: 1-408-962-4259 or via email at ron.richter@siliconimage.com .
About Silicon Image, Inc.
Silicon Image, Inc. is a leading provider of semiconductor and intellectual property products for the secure distribution, presentation and storage of high-definition content. With a rich history of technology innovation that includes creating industry standards such as DVI and HDMI, the company’s solutions facilitate the use of digital content amongst consumer electronics, personal computer (PC) and storage devices, with the goal to securely deliver digital content anytime, anywhere and on any device. Founded in 1995, the company is headquartered in Sunnyvale, California, with regional engineering and sales offices in China, Germany, Japan, Korea, Taiwan and the United Kingdom. For more information, please visit www.siliconimage.com .
Forward-looking Statements
This news release contains forward-looking statements within the meaning of federal securities laws and regulations, including, but not limited to, statements regarding the anticipated performance, cost and time-to-market benefits of Silicon Image’s HDMI v1.3 PHY and IP core solution. These forward-looking statements involve risks and uncertainties, including those described from time to time in Silicon Image’s filings with the Securities and Exchange Commission (SEC), that could cause the actual results to differ materially from those anticipated by these forward-looking statements. Silicon Image assumes no obligation to update any forward-looking statement.
Silicon Image and the Silicon Image logo are trademarks, registered trademarks or service marks of Silicon Image, Inc. in the United States and/or other countries. HDMI is a trademark or registered trademark of HDMI Licensing, LLC in the United States and/or other countries. All other trademarks and registered trademarks are the property of their respective owners in the Unites States and/or other countries.
Contact:
Silicon Image, Inc.
Gabriele Collier, 408-616-4088
gabriele.collier@siliconimage.com
or
Ogilvy
Public Relations for Silicon Image, Inc.
Ian Yellin, 415-677-2714
ian.yellin@ogilvypr.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom